Global
Search    
Include All CSL Behring Country Sites

Pulmonary

CSL Behring's human alpha1-proteinase inhibitor, also known as Zemaira, helps patients helps patients maintain alpha-1 proteinase inhibitor levels.
Alpha1-proteinase inhibitors (A1-PI) are used in the treatment of Alpha1-proteinase inhibitor deficiency (A1-PI deficiency or Alpha-1). Proteinase inhibitors are proteins that block the action of peptidases, enzymes that degrade protein.

A1-PI deficiency is a hereditary disorder that can result in emphysema -- a chronic, obstructive lung disease. If left untreated, emphysema can lead to severe tissue damage and death.

A1-PIs inhibit lung tissue degradation and are indicated as maintenance therapy for patients with A1-PI deficiency with clinical evidence of emphysema.

Treatment

Human alpha1-proteinase inhibitor is indicated for maintenance therapy for patients with A1-PI deficiency and clinical evidence of emphysema.

Product Name Nonproprietary Name Product Description Web Site
Zemaira® Human alpha1-proteinase inhibitor Freeze-dried alpha1-proteinase inhibitor
(A1-PI)
www.zemaira.com